Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 275.73M |
| Revenue (ttm) | 196.49M |
| Net Income (ttm) | -259.47M |
| Shares Out | 68.08M |
| EPS (ttm) | -3.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 516,380 |
| Open | 3.980 |
| Previous Close | 3.960 |
| Day's Range | 3.965 - 4.170 |
| 52-Week Range | 1.575 - 19.950 |
| Beta | -0.68 |
| Analysts | Buy |
| Price Target | 7.60 (+87.65%) |
| Earnings Date | Nov 7, 2024 |
About AMLX
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AMLX stock is "Buy." The 12-month stock price forecast is $7.6, which is an increase of 87.65% from the latest price.
News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp...
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexi...
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference.
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 O...
Best Cheap Stocks To Buy Now (Under $10)
If you're willing to take on the risk of owning cheap stocks, these five picks are all priced at or under $10.
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee ...
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results.
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024.
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial.
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024.
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breac...
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor...
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of exploratory analyses on cerebrospinal fluid (CSF...
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2024 Earnings Call Transcript August 8, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - ...
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results.
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024.
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives Orphan Drug Designation from the European Commission for AMX0035 for the Treatment of Wolfram Syndrome.
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals Inc AMLX acquired avexitide from Eiger BioPharmaceuticals Inc EIGRQ for $35.1 million.
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Avexitide Acquisition Conference Call July 10, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Kle...
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation.
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx' management team will host a conference call and webcas...
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initia...
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.